

**IN THE CLAIMS:**

This listing of the claims replaces all prior versions and listings of the claims.

Please amend the claims as follows.

Claims 1 to 134. (Canceled)

135. (Currently amended) A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof

i) an effective amount of at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof, and

ii) an effective amount of at least one additional compound selected from gabapentin, pregabalin, a pharmaceutically acceptable salt of pregabalin, or a combination thereof, pramipexole, L-DOPA, tiyanidine, clonidine, tramadol, morphine, codeine, and carbamazepine, and pharmaceutically acceptable salts thereof; with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan.

136-145. (Canceled)

146. (Currently amended) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in the same dosage form.

147. (Currently amended) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in separate dosage forms.

148. (Currently amended) The method of claim 147, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are administered simultaneously.

149. (Currently amended) The method of claim 147, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are administered separately.

150. (Currently amended) The method of claim 146, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in the same oral dosage form.

151. (Currently amended) The method of claim 147, wherein the milnacipran and at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least [[on]] one additional compound are in separate oral dosage forms.

152. (Currently amended) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof is in tablet form.

153-188. (Canceled)